��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2005, 31(1) 35-37 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	ϸ��
	ӲƤ��,ϵͳ��
	ת��Ӧ�
	��
	��
	��Ƽ
	PubMed
	Article by
	Article by

ϸ��ӲƤ��о��չ

��, ��Ƽ

��ҽѧԺ��һ��ҽԺƤ�� 650032

ժҪ��

ϸ��ɻϸ��ڵľ��е��ڶ��ϸ��ֻ�,��Ӧ��,��֢��Ӧ��ٽ��ϵȶ��ѧ��ܵ�С��Ӷ��ġ�ӲƤ��ķ��Ʋ��ʮ��,��о��,��ϸ��ͨ��ͬ��;��ӲƤ��չ,�ر��ת��Ӧºͽ��֯��ǵ��ӲƤ��֯��ά��Ӳ��Ҫ��ء�

�ؼ���� ϸ�� ӲƤ��,ϵͳ�� ת��Ӧ�

Abstract:

Keywords:

�ո�� 2004-04-23 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Riccieri V, Rinaldi T, Spadaro A, et al. Interleukin-13 in systemic sclerosis:relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol, 2003,22:102-106.
[2] Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum,2000,43:2455-2463.
[3] Choi JJ, Min DJ, Cho ML, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol, 2003,30:1529-1533.
[4] Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis:increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res, 2002,4:R1 1.
[5] Tsuji-Yamada J, Nakazawa M, Minami M, et al. Increased frequency of interleukin 4 producing CD4 + and CD8 + cells in peripheral blood from patients with systemic sclerosis. J Rheumatol,2001,28 :12528.
[6] Neiko IeM, Iatsyshyn RI. Role of interleukin-1 and interleukin-2 in the pathogenesis of systemic scleroderma. Fiziol Zh, 2002,48:56-61.
[7] Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol, 2001,31:2936-2941.
[8] Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis:role of plateletderived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum,2001,44:2665-2678.
[9] Postiglione L, Montagnani S, Riccio A, et al. Enhanced expression of the receptor for granulocyte macrophage colony stimulating factor on dermal fibroblasts from scleroderma patients. J Rheumatol, 2002,29:94-101.
[10] Ihn H. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp (Warsz), 2002,50:325.
[11] Susol E, Rands AL, Herrick A, et al. Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis. Rheumatology (Oxford), 2000,39:1332-1336.
[12] Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum,2003, 48:1964-1978.
[13] Sato M, Shegogue D, Gore EA, et al. Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J Invest Dermatol, 2002,118:704.
[14] Leask A, Holmes A, Abraham DJ. Connective tissue growth factor:a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep, 2002,4:136-142.
[15] Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci, 2001,27:140-146.
[16] Murota H, Hamasaki Y, Nakashima T, et al. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts. Arthritis Rheum, 2003, 48:1117-1125.
[17] Mouthon L, Garcia De La Pena-Lefebvre P, Chanseaud Y, et al.Pathogenesis of systemic scleroderma:immunological aspects. Ann Med Interne (Paris), 2002,153:167-178.
[18] Martinez JA, Nishimura C, Guatura SR, et al. Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Rheumatol Int, 2001,21:122-126.
[19] Furuse S, Fujii H, Kaburagi Y, et al. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol, 2003,30:1524-1528.
[20] Sato S, Hanakawa H, Hasegawa M, et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol, 2000,27:2838-2842.
[21] Suzuki J, Morimoto S, Amano H, et al. Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol,2001,28 :2389.
[22] Matucci-Cerinic M, Giacomelli R, Pignone A, et al. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). Ann Rheum Dis, 2001,60:487-494.
[23] Kawaguchi Y, Harigai M, Hara M, et al. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis. J Rheumatol, 2002, 29:1877-1883.

��е��

1��,��,.UVB�Խ��γ�ϸ��ϸ��ӵ�Ӱ��[J]. ��Ƥ��Բ�ѧ��־, 2007,33(4): 231-

2��С��,��.Th1/Th2ϸ��ֳ��Ĺ�ϵ�о��״[J]. ��Ƥ��Բ�ѧ��־, 2006,32(1): 54-

3��,�浤.��ϸ��ƶ��Ƥ��Ե��о��չ[J]. ��Ƥ��Բ�ѧ��־, 2006,32(2): 127-

4��, ֣��.T�ܰ�ϸ��ϸ��м��ķ��ϵ[J]. ��Ƥ��Բ�ѧ��־, 2007,33(6): 346-348

5��, ��.�ʴ�ϸ��Ӧ��Ƥ�׷��е��о��չ[J]. ��Ƥ��Բ�ѧ��־, 2007,33(6): 372-374

6��ݺ�Ӣ,��,��ѧ��.��߷��԰׽��ϸ��ӵ�Ӱ��[J]. ��Ƥ��Բ�ѧ��־, 2008,34(2): 116-118

7��ֺ��,��.��м��Tϸ��õĽ�չ[J]. ��Ƥ��Բ�ѧ��־, 2008,34(5): 310-312

8��տ��,��,֣־��.��м��ϸ��ϸ��ӵ��[J]. ��Ƥ��Բ�ѧ��־, 2008,34(6): 385-387

9��,��,.ϸ��ڰ��緢��е��[J]. ��Ƥ��Բ�ѧ��־, 2009,35(1): 42-44

10��,��,.��ϻ�Ƥ��ͻϸ��ϸ��ӵı仯[J]. ��Ƥ��Բ�ѧ��־, 2009,35(1): 48-49

11�� ɵt ��.��ٻ��ܰ�ϸ��Ƥ��Ĥ��е��[J]. ��Ƥ��Բ�ѧ��־, 2010,36(2): 110-112